NCCN Guidelines® Insights - Soft Tissue Sarcoma, Version 1.2021
The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including the development of a separate and distinct guideline for gastrointestinal stromal tumors (GISTs); reconception of the management of desmoid tumors; inclusion of further recommendations for the diagnosis and management of extremity/body wall, head/neck sarcomas, and retroperitoneal sarcomas; modiﬁcation and addition of systemic therapy regimens for sarcoma subtypes; and revision of the principles of radiation therapy for soft tissue sarcomas.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Soft Tissue Sarcoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Soft Tissue Sarcoma
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kaneﬁeld; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Margaret von Mehren, MD, Panel Chair, has disclosed that she receives grant/research support from Blueprint Medicines, Deciphera Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Arog, Gradalis, and Spring Works Therapeutics.
John M. Kane III, MD, Panel Vice Chair, has disclosed that he has no relevant ﬁnancial relationships.
Kristen N. Ganjoo, MD, Panel Member, has disclosed that she is a scientiﬁc advisor for Foundation Medicine.
Edward Kim, MD, Panel Member, has disclosed that he has no relevant ﬁnancial relationships.
David Liebner, MD, Panel Member, has disclosed that he is a scientiﬁc advisor for Foundation Medicine, Blueprint Medicines, and Epizyme.
Martin McCarter, MD, Panel Member, has disclosed that he has no relevant ﬁnancial relationships.
Alberto S. Pappo, MD, Panel Member, has disclosed that he has received consulting fees from Bayer Healthcare, Iqvia, and UpToDate.
Amanda M. Parkes, MD, Panel Member, has disclosed that she has received consulting fees from Daiichi-Sankyo Co. and Deciphera Pharmaceuticals, Inc.
Matthew Poppe, MD, Panel Member, has disclosed that he has equity interest/stock options in AstraZeneca Pharmaceuticals LP, Johnson & Johnson, Merck & Co., Inc., Inovio Pharmaceuticals, Inc., Moderna, Inc., PEEL Therapeutics, Inc., and sanoﬁ-aventis U.S.
Richard F. Riedel, MD, Panel Member, has disclosed that he receives grant/research support from AADi, AROG, Blueprint Medicines, Daiichi-Sankyo, Decipherma Pharmaceuticals, GlaxoSmithKline, Immune Design, Karyopharm Therapeutics, NanoCarier, Oncternal, Philogen, Plexxikon, Roche Laboratories, Springworks, and TRACON Pharmaceuticals; and that he is a scientiﬁc advisor for Bayer HealthCare, Blueprint Medicines, Daiichi-Sankyo, Deciphera Pharmaceuticals, and NanoCarrier.
Brian Rubin, MD, PhD, Panel Member, has disclosed that he receives consulting fees from Eli Lilly and Company, is a scientiﬁc advisor for Avalon Healthcare Solutions and PathAI, receives other ﬁnancial beneﬁt from Blueprint Medicines.
Mary Anne Bergman, Guidelines Coordinator, NCCN, has disclosed that she has no relevant ﬁnancial relationships.
Giby V. George, MD, Oncology Scientist/Medical Writer, NCCN, has disclosed that he has no relevant ﬁnancial relationships.
To view all of the conﬂicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-20-013-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 10, 2021. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation